glp 1 tirzepatide mounjaro Use of the dual GIP/GLP-1 drug (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort Weighing in on GLP-1 Weight
Description
The incidence of vomiting increases
Twelve month results and long-term outcomes The 12-month checkpoint provides the most reliable data on tirzepatide efficacy and sustainability
The class of treatments, which include Novo Nordisks Ozempic and Wegovy and Eli LIllys Mounjaro, have gastrointestinal side effects like nausea, vomiting and delayed stomach emptying
Comparing 10mg vials to other tirzepatide vial sizes The 10mg vial is one of several sizes available for compounded tirzepatide
